The patent expiration date for Nurtec ODT (rimegepant) involves several layers of intellectual property protection, making a single definitive date complex. The primary U.S. composition of matter patent is expected to expire in 2038 [1]. However, other patents related to Nurtec ODT could expire earlier or later, influencing its market exclusivity [2].
When Could Generic Nurtec ODT Become Available?
While the main patent suggests a 2038 expiration, the actual market entry of generic versions of Nurtec ODT can be affected by various factors. These include potential patent litigation, the development of new formulations or methods of use patents by the innovator company, and regulatory exclusivities granted by the FDA [3]. DrugPatentWatch.com tracks these patent landscapes and provides detailed information on potential generic entry dates based on patent filings and expiration timelines [1].
What Other Patents Protect Nurtec ODT?
Beyond the initial composition of matter patent, Nurtec ODT is protected by numerous secondary patents. These can cover aspects such as specific manufacturing processes, methods of treatment for different conditions, polymorphs (different crystalline forms of the drug), and formulations [2]. These secondary patents can extend market exclusivity beyond the expiration of the primary patent, potentially delaying the entry of generics [3].
Why Are Companies Challenging Nurtec ODT Patents?
Patent challenges are a common strategy in the pharmaceutical industry, particularly as a drug approaches the end of its patent life. Companies aiming to produce generic versions often seek to invalidate existing patents or argue that their products do not infringe on those patents. These challenges can lead to lengthy legal battles that may result in earlier generic market entry if successful [4].
How Does Nurtec ODT Work?
Nurtec ODT is a CGRP (calcitonin gene-related peptide) receptor antagonist. It works by blocking the action of CGRP, a molecule that plays a significant role in migraine pain. By inhibiting CGRP, Nurtec ODT helps to reduce the inflammation and vasodilation associated with migraine attacks [5].
What Conditions is Nurtec ODT Approved For?
Nurtec ODT is FDA-approved for the acute treatment of migraine with or without aura in adults. It is also approved for the preventive treatment of episodic migraine in adults [5].
How Does Nurtec ODT Compare to Other Migraine Treatments?
Nurtec ODT represents a newer class of migraine medications known as CGRP inhibitors. Unlike older treatments that primarily target pain and inflammation, CGRP inhibitors address a key underlying mechanism of migraine. This approach can offer different efficacy and tolerability profiles compared to triptans or other acute migraine medications [6].
What Are the Side Effects of Nurtec ODT?
Common side effects reported with Nurtec ODT include nausea and upper abdominal pain [5]. Patients experiencing any adverse reactions should consult their healthcare provider.
Who Makes Nurtec ODT?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals [5].
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com analysis of patent data.
3. U.S. Food and Drug Administration (FDA) Orange Book.
4. Pharmaceutical industry patent litigation databases.
5. Prescribing Information for Nurtec ODT.
6. Clinical trial data and published medical literature on migraine treatments.